Skip to main content
SpringerLink
Log in

What may be the best menopausal hormone treatment?

  • News and Views
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

Data availability is supplied up on request.

References

  1. Flores VA, Pal L, Manson JE (2021) Recommended hormone therapy in menopause: concepts, controversies and approach to treatment. Endocr Rev. https://doi.org/10.1210/endrev/bnab011. (Online ahead of print. PMID: 33858012)

    Article  PubMed  Google Scholar 

  2. Langer RD, Hodis HN, Lobo RA, Allison MA (2021) Hormone replacement therapy - where are we now? Climacteric 24:3–10. https://doi.org/10.1080/13697137.2020.1851183

    Article  CAS  PubMed  Google Scholar 

  3. Rossouw JE, Anderson GL, Prentice RL, Writing group for the women’s health initiative Investigators et al (2002) Risks and benefits of estrogen plus progestin for healthy postmenopausal women. JAMA 288:321–33

    Article  CAS  PubMed  Google Scholar 

  4. Women’s Health Initiative Investigators. Protocol for the clinical trial and observational study components. Available from: https://www-whi-org.s3.us-west-2.amazonaws.com/wp-content/uploads/Protocol-1993-2005.pdf

  5. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL et al (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523–534

    Article  CAS  PubMed  Google Scholar 

  6. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE et al (1991) Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med 325:756–62

    Article  CAS  PubMed  Google Scholar 

  7. Barrett-Connor E, Grady D (1998) Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19:55–72

    Article  CAS  PubMed  Google Scholar 

  8. Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P (2008) Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 90:642–672

    Article  PubMed  Google Scholar 

  9. Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647–1657

    Article  CAS  PubMed  Google Scholar 

  10. Chlebowski RT, Anderson GL, Aragaki AK et al (2020) Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA 324:369–380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394:1159–1168

    Article  PubMed Central  Google Scholar 

  12. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J (2017) Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 1:CD00143. https://doi.org/10.1002/14651858.CD004143.pub5

    Article  Google Scholar 

  13. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH (2010) Postmenopausal hormone therapy: an endocrine society scientific statement. J Clin Endocrinol Metab 95(7 Suppl 1):s1–s66

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Blumenfeld Z, Boulman N, Leiba R, Siegler E, Shachar S, Linn R, Levy Y (2007) High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scand J Clin Lab Invest 67:257–263

    Article  CAS  PubMed  Google Scholar 

  15. Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the women’s health initiative randomized trials. JAMA 310:1353–1368

    Article  CAS  PubMed  Google Scholar 

  16. Genazzani AR, Monteleone P, Giannini A, Simoncini T (2021) Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice. Hum Reprod Update. https://doi.org/10.1093/humupd/dmab026

    Article  PubMed  Google Scholar 

  17. Shufelt CL, Merz CN, Prentice RL et al (2014) Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the women’s health initiative observational study. Menopause 21:260–266

    Article  PubMed  PubMed Central  Google Scholar 

  18. Simon JA, Laliberte F, Duh MS et al (2016) Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause 23:600–610

    Article  PubMed  Google Scholar 

  19. Vinogradova Y, Coupland C, Hippisley-Cox J (2019) Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the Q Research and CPRD databases. BMJ 364:k4810

    Article  PubMed  PubMed Central  Google Scholar 

  20. Ridker PM (2018) Clinician’s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J Am Coll Cardiol 72:3320–3331

    Article  PubMed  Google Scholar 

  21. Ridker PM, Hennikens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the predictor of cardiovascular disease in women. New Engl J Med 342:836–843

    Article  CAS  PubMed  Google Scholar 

  22. Pearson TA, Mensah GA, Alexander RW (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the center for disease control and prevention and the American heart association. Circulation 107:499–511

    Article  PubMed  Google Scholar 

  23. Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107:391–397

    Article  PubMed  Google Scholar 

  24. Wanpen V, Meryem T, Zhongyun W, Debbie A, Borna M, Ishwarlal J (2003) Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 41:1358–1363

    Article  Google Scholar 

  25. Strandberg TE, Ylikorkala O, Tikkanen MJ (2003) Differing effect of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy women. Am J Cardiol 92:212–214

    Article  CAS  PubMed  Google Scholar 

  26. Neven P, Amant F, Poppe W, Van den Broecke R (2009) Levonorgestrel-releasing intrauterine systems (LNG-IUS) and breast cancer. Fertil Steril 91:e5

    Article  PubMed  Google Scholar 

  27. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA (2008) Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 90:17–22

    Article  CAS  PubMed  Google Scholar 

  28. Fu Y, Zhuang Z (2014) Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis. Int J Clin Exp Pathol. 7:6419–6429

    PubMed  PubMed Central  Google Scholar 

  29. Conz L, Mota BS, Bahamondes L, TeixeiraDória M, Françoise MauricetteDerchain S, Rieira R, Sarian LO (2020) Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 99(8):970–982

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The authors have not disclosed any funding.

Author information

Authors and Affiliations

  1. Reproductive Endocrinology, Ob/Gyn, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, 3 Ehud St, 3455205, Haifa, Israel

    Zeev Blumenfeld

  2. Rambam Health Care Campus, Haifa, Israel

    Ronit Leiba

  3. Meuhedet Health Services, Haifa, Israel

    Zeev Blumenfeld & Tamar Stam

Authors
  1. Zeev Blumenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronit Leiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tamar Stam
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZB—project development, data collection, manuscript writing. RL—data collection, manuscript writing. TS—data collection, manuscript writing.

Corresponding author

Correspondence to Zeev Blumenfeld.

Ethics declarations

Conflict of interest

No conflict of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blumenfeld, Z., Leiba, R. & Stam, T. What may be the best menopausal hormone treatment?. Arch Gynecol Obstet 307, 659–662 (2023). https://doi.org/10.1007/s00404-022-06889-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-022-06889-3

Search

Navigation